Gene · 27329
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Common Single Nucleotide Polymorphisms in Clinical Cardiology and Dietary Intervention: A Narrative Review. | Nutrients | 2026 | 42514439 | PubTator, text mining | PubMed |
| Longer-Term Efficacy and Safety of Zodasiran in Patients with Mixed Hyperlipidaemia. | Eur J Prev Cardiol | 2026 | 42496147 | PubTator, text mining | PubMed |
| Cardiorenal Protective Effects of Finerenone in Patients with Type 2 Diabetes Mellitus. | Arch Intern Med Res | 2026 | 42491982 | PubTator, text mining | PubMed |
| Evinacumab Treatment of Homozygous Familial Hypercholesterolemia Patients in a Real-World Setting: An Overview After the First Year of Therapy. | AACE Endocrinol Diabetes | 2026 | 42491512 | PubTator, text mining | PubMed |
| Base editing for precision therapeutics. | Cell Genom | 2026 | 42486091 | PubTator, text mining | PubMed |
Lipids and abdominal aortic aneurysm: from pathophysiology to therapy. A call to action from the Italian Society for the Study of Atherosclerosis and the Italian Society for Angiology and Vascular Medicine. | Nutr Metab Cardiovasc Dis | 2026 | 42476858 | PubTator, text mining | PubMed |
| Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation. | Curr Atheroscler Rep | 2026 | 42474848 | PubTator, text mining | PubMed |
| Precise hepatic base editing of ASGR1 enables robust and durable LDLR-independent lipid lowering in vivo. | Mol Ther | 2026 | 42470100 | PubTator, text mining | PubMed |
| Homozygous familial hypercholesterolemia, experience with Evinacumab treatment in two Mexican pediatric patients: case report. | Front Genet | 2026 | 42460149 | PubTator, text mining | PubMed |
| Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant. | Respir Res | 2026 | 42458495 | PubTator, text mining | PubMed |
| Gene Silencing of ANGPTL3 Induces PCSK9: Exploring the Biological Significance in the Hepatoma Huh7 Cell Line. | Cells | 2026 | 42439671 | PubTator, text mining | PubMed |
| The Angiopoietin-like Protein (ANGPTL) Axis in Dyslipidemia: Mechanisms, Cardiovascular Risk, and Emerging Therapies. | Curr Atheroscler Rep | 2026 | 42435249 | PubTator, text mining | PubMed |
| SLIT2 and ANGPTL3 as putative mediators linking obesity to atrial fibrillation: A Mendelian randomization study. | Medicine (Baltimore) | 2026 | 42410793 | PubTator, text mining | PubMed |
| Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial. | J Atheroscler Thromb | 2026 | 42386604 | PubTator, text mining | PubMed |
| Revisiting the Lipid-Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology. | Biomolecules | 2026 | 42352298 | PubTator, text mining | PubMed |
| Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives. | Biomolecules | 2026 | 42352274 | PubTator, text mining | PubMed |
| Relationship Between Adipose Tissue and Liver Dysfunction in Women with Polycystic Ovary Syndrome and Metabolic Syndrome. | Metabolites | 2026 | 42346373 | PubTator, text mining | PubMed |
| Extracellular vesicle cargo dynamics in the bone marrow microenvironment: from hematopoietic homeostasis to malignant transformation. | Extracell Vesicle | 2026 | 42344609 | PubTator, text mining | PubMed |
| Urinary ANGPTL3: a novel noninvasive biomarker for podocyte injury in pediatric glomerular diseases. | J Transl Med | 2026 | 42337674 | PubTator, text mining | PubMed |
| Individuals who deviate from polygenic expectation are enriched for damaging variants in genes linked to rare disease. | Am J Hum Genet | 2026 | 42330953 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27329/papers?page=2